GenoFocus (Korea) Performance
| 187420 Stock | 4,565 85.00 1.83% |
GenoFocus has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.96, which attests to possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning GenoFocus are expected to decrease slowly. On the other hand, during market turmoil, GenoFocus is expected to outperform it slightly. GenoFocus right now retains a risk of 4.2%. Please check out GenoFocus coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to decide if GenoFocus will be following its current trending patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in GenoFocus are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, GenoFocus may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
| Total Cashflows From Investing Activities | -6.9 B |
GenoFocus |
GenoFocus Relative Risk vs. Return Landscape
If you would invest 432,500 in GenoFocus on November 2, 2024 and sell it today you would earn a total of 27,500 from holding GenoFocus or generate 6.36% return on investment over 90 days. GenoFocus is generating 0.1905% of daily returns and assumes 4.1978% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than GenoFocus, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GenoFocus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GenoFocus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GenoFocus, and traders can use it to determine the average amount a GenoFocus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0454
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 187420 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.2 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average GenoFocus is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GenoFocus by adding it to a well-diversified portfolio.
GenoFocus Fundamentals Growth
GenoFocus Stock prices reflect investors' perceptions of the future prospects and financial health of GenoFocus, and GenoFocus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GenoFocus Stock performance.
| Return On Equity | -24.42 | |||
| Return On Asset | -0.0291 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 231.24 B | |||
| Shares Outstanding | 21.54 M | |||
| Price To Sales | 9.72 X | |||
| Revenue | 25.87 B | |||
| EBITDA | (2.54 B) | |||
| Cash And Equivalents | 25.11 B | |||
| Total Debt | 26.94 B | |||
| Cash Flow From Operations | (2.39 B) | |||
| Total Asset | 118.52 B | |||
About GenoFocus Performance
By analyzing GenoFocus' fundamental ratios, stakeholders can gain valuable insights into GenoFocus' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GenoFocus has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GenoFocus has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about GenoFocus performance evaluation
Checking the ongoing alerts about GenoFocus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GenoFocus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GenoFocus had very high historical volatility over the last 90 days | |
| The company reported the revenue of 25.87 B. Net Loss for the year was (8.53 B) with profit before overhead, payroll, taxes, and interest of 6.06 B. | |
| GenoFocus has accumulated about 25.11 B in cash with (2.39 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
- Analyzing GenoFocus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GenoFocus' stock is overvalued or undervalued compared to its peers.
- Examining GenoFocus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GenoFocus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GenoFocus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GenoFocus' stock. These opinions can provide insight into GenoFocus' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for GenoFocus Stock analysis
When running GenoFocus' price analysis, check to measure GenoFocus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GenoFocus is operating at the current time. Most of GenoFocus' value examination focuses on studying past and present price action to predict the probability of GenoFocus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GenoFocus' price. Additionally, you may evaluate how the addition of GenoFocus to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |